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Abstract The relationship between lipid levels and risk of
venous thrombosis is not well established. We aimed to
assess the association between several lipids and risk of
venous thrombosis using data from a population-based
case–control study, and to evaluate the underlying mech-
anism, considering confounding by common risk factors
and mediation via hemostatic factors and C-reactive pro-
tein. From the Multiple Environmental and Genetic
Assessment of risk factors for venous thrombosis (MEGA)
study, 2234 patients with a first venous thrombosis and
2873 controls were included. Percentile categories of total/
low-density lipoprotein/high-density lipoprotein choles-
terol, triglycerides, and apolipoproteins B and A1 were
established in controls (\10th, 10th–25th, 25th–75th [ref-
erence], 75th–90th,[90th percentile). In age- and sex-ad-
justed models, decreasing levels of apolipoproteins B and
A1 were dose-dependently associated with increased
thrombosis risk, with odds ratios of 1.35 (95% confidence
interval 1.12–1.62) and 1.50 (95% confidence interval
1.25–1.79) for the lowest category versus the reference
category, respectively. The dose–response relation
remained with further adjustment for body mass index,
estrogen use, statin use, and diabetes. Although
apolipoproteins B and A1 were associated with several
hemostatic factors and C-reactive protein, none explained
the increased risk in mediation analyses. The other lipids
were not associated with venous thrombosis risk. In con-
clusion, decreasing levels of apolipoproteins B and A1
were associated with increased risk of venous thrombosis.
Our findings are consistent with experimental data on the
anticoagulant properties of apolipoproteins B and A1.
These findings need to be confirmed and the underlying
mechanism further investigated.
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Introduction
Venous thrombosis and arterial cardiovascular disease
have been traditionally regarded as separate diseases with
distinct causes and treatment. However, several studies in
the past decade have shown that patients with venous
thrombosis (i.e., deep vein thrombosis or pulmonary
embolism) have an increased risk of subsequent arterial
disease [1]. As lipid levels can be modulated by lifestyle
intervention and drug therapy [2], the potential association
between lipids and venous thrombosis and the related
pathophysiology is a relevant clinical issue worth pursuing.
Indeed, previous data have shown that lipid-lowering drugs
(statins, most notably rosuvastatin) are associated with a
decreased risk of venous thrombosis [3–5], which might
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indicate a possible role for lipids in the pathophysiology of
venous thrombosis. However, whether lipids are associated
with venous thrombosis is not known in detail due to
controversial results among epidemiological studies
[6–13].
The association between lipid levels and venous
thrombosis might be explained by common factors that are
related to both lipids and risk of venous thrombosis (con-
founders), such as age [14–16], sex [11, 14, 15], lifestyle
[2, 17], body mass index (BMI) [2, 15, 16], estrogen use
[15, 16, 18], statin use [3–5, 19], and diabetes mellitus
[2, 20] (Fig. 1). If causal, the association could be
explained by factors that are a consequence of lipid prop-
erties on hemostasis [21] and inflammation [22] (mediators
in the causal pathway) (Fig. 1). These might increase the
risk of venous thrombosis and could include changes in
levels of hemostatic factors [16] and C-reactive protein
(CRP) [10].
Therefore, the aim of our study was to assess the asso-
ciation between lipid levels and risk of venous thrombosis,
and to evaluate the underlying mechanism, with particular
attention to confounding and mediation via hemostatic
factors and CRP. For this purpose, we used data of a large,
population-based case–control study on the etiology of
venous thrombosis [Multiple Environmental and Genetic
Assessment of risk factors for venous thrombosis (MEGA)
study]. In the present analysis, we included the major lipid
analytes, i.e., total cholesterol (TC), low-density lipopro-
tein cholesterol (LDL-C), high-density lipoprotein choles-
terol (HDL-C), and triglycerides. We also analysed
apolipoprotein A1 (apo A1), which is the major protein
component of HDL-C [23], and apolipoprotein B (apo B),
which is the protein component of the very low-density/
low-density lipoprotein spectrum (apo B-containing
lipoproteins) [23].
Methods
Study design
Between March 1999 and September 2004, consecutive
patients aged 18–70 years with a first objectively confirmed
deep vein thrombosis or pulmonary embolism were included
in the MEGA study from 6 anticoagulation clinics in the
Netherlands [24]. For the current analysis, patients with arm
vein thrombosis and participants with active or previous
history of malignancy within 5 years before the index date,
and participants with missing data on malignancy were
excluded. In the MEGA study, blood sampling was deter-
mined by calendar time, i.e., for logistic reasons participants
were asked to provide blood samples up to June 2002 only
[24]. Of the 4463 patients eligible for this study, 2237 pro-
vided blood samples (Fig. 2). Controls were included from 2
sources: partners of patients and subjects reached by random
digit dialing (RDD) [24] (Fig. 2). Of the 3222 eligible part-
ners (aged 18–70 years, and without venous thrombosis),
1459 provided blood. Of the 2939 eligible RDD controls
(frequency matched for age and sex to the patients, and
without venous thrombosis), 1422 provided blood. This study
was approved by the Ethics Committee of the Leiden
University Medical Center, and written informed consent was
obtained from all participants. The MEGA study has been
conducted according to the principles expressed in the Dec-
laration of Helsinki and described in detail elsewhere [24].
Data collection and blood sampling
All participants were asked to complete a questionnaire on
many potential risk factors for venous thrombosis [24]. Of
interest for this analysis are the items on body weight and
height, lifestyle, estrogen- and statin-use, and self-reported
Fig. 1 Causal diagram of the
association between lipid levels
and venous thrombosis
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diabetes. BMI was calculated by dividing weight (kg) by
height squared (m2). A BMI between 18.5 and 25 kg/m2
was defined as normal, between 25 and 30 kg/m2 as
overweight and[30 kg/m2 as obesity. The index date was
defined as the date of diagnosis of venous thrombosis for
patients and their partners, and the date of completing the
questionnaire for RDD controls. At least 3 months after
discontinuation of anticoagulation, or during anticoagulant
therapy in patients who continued this therapy for more
than 1 year, patients and controls visited the anticoagula-
tion clinic for an interview and blood sampling.
Laboratory measurements
Lipids were measured on stored (-80 C) and previously
unthawed fasting serum samples. TC and triglycerides were
measured by a colorimetric method (CHOD-PAP for TC and
GPO-PAP for triglycerides) on a Modular P analyser (Roche
Diagnostics, Mannheim, Germany). HDL-C was measured
by a direct method based on the Kyowa Medex reaction
principle using polyethylene glycol (PEG)-modified enzymes
(Roche Diagnostics, Mannheim, Germany). Apo A1 and apo
B were measured by immunoturbidimetric assays on a Cobas
Integra analyzer (Roche Diagnostics, Mannheim, Germany).
LDL-C levels were estimated using the Friedewald formula
[LDL-C = TC - HDL-C - (triglycerides/2.2) for mmol/L]
[25], and when triglycerides exceeded 4.52 mmol/L, LDL-C
was not estimated. The natural anticoagulants (antithrombin,
protein C, and total protein S), the procoagulant factors (fib-
rinogen, factors II, VII, VIII, IX, X and XI, and von Wille-
brand factor), clot lysis time, and CRP levels were determined
according to methods previously described [26, 27]. Total
tissue factor pathway inhibitor (TFPI) activity levels were
assessed in citrated plasma by measuring TFPI inhibition of
the catalytic tissue factor (TF)-factor VIIa (FVIIa) complex
using the Actichrome TFPI activity assay (Sekisui Diagnos-
tics, Stamford, CT, USA); one unit of TFPI activity corre-
sponds to 55 ng/ml plasma TFPI. All laboratory analyses
were performed without knowledge of whether the sample
was from a patient or a control subject.
Statistical analyses
Demographic and clinical characteristics related to lipid
levels in controls
To obtain insight in potential confounding variables, we
estimated in the pooled control group (partner and RDD
Fig. 2 Flow chart of the
Multiple Environmental and
Genetic Assessment of risk
factors for venous thrombosis
(MEGA) study. RDD random-
digit dialing
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controls) mean differences and their 95% confidence
intervals (CIs) in lipid levels by linear regression in relation
to age (50–70 years vs. 18–50 years [reference]), sex
(women vs. men [reference]), BMI (overweight/obesity vs.
normal weight [reference]), self-reported diabetes (yes vs.
no [reference]), estrogen use at blood sampling (users vs.
nonusers [reference]), and statin use (users vs. nonusers
[reference]). All lipids were normally distributed, with the
exception of triglycerides (right-skewed distribution),
which levels were log-transformed. In our regression
models, each lipid was entered as the dependent variable,
and the demographic or clinical characteristics (i.e., age,
sex, BMI, self-reported diabetes, estrogen use at blood
sampling, and statin use) were the independent variables.
The resulting regression coefficient (b) for a clinical or
demographic characteristic indicated the mean difference
in lipid levels between the reference and the other category
of that particular characteristic. When applicable, mean
differences and their 95% CIs were adjusted for age
(continuous) and sex, and further for the other aforemen-
tioned characteristics.
Lipid levels and risk of venous thrombosis
Lipid categories were defined according to the values
measured in the pooled control group (\10th, 10th–25th,
25th–75th, 75th–90th, and[90th percentile). Age- and sex-
adjusted odds ratios (OR) and their 95% CIs were calcu-
lated as estimates of the relative risk of venous thrombosis
for the different lipid categories in comparison with the
reference category (25th–75th percentiles) by uncondi-
tional logistic regression. We further adjusted for other
potential confounders to assess whether an increased
thrombosis risk could be explained by these factors i.e.:
estrogen use at blood sampling (dichotomous value), BMI
(continuous values), statin use (dichotomous value), and
self-reported diabetes (dichotomous value).
Dyslipidemia may be related to lifestyle [2], which may
affect venous thrombosis risk [17], and therefore lifestyle
may act as another confounder. Such behavior is not easily
measured and adjusted for. Partners of patients are likely to
resemble the patients in lifestyle, and therefore we per-
formed an additional 1:1 matched analysis by conditional
logistic regression which adjusts for associations within
matched couples. This method fully takes matching into
account, with adjustment for all unmeasured factors for
which couples tend to be similar (e.g., socioeconomic
class) [28]. In this analysis, all aforementioned potential
confounders were additionally adjusted for as covariates.
Although using partners as controls results in most controls
having the opposite sex as their matched case, one can
adjust for sex in a partner-matched case–control study by
adding sex to the model [28].
Mediation analyses
In case an association between lipid levels and venous
thrombosis is present, a mediation analysis is useful to
assess whether this association could be explained by
factors related to hemostasis and inflammation. First, we
investigated whether lipid levels were associated with
changes in hemostatic factor and CRP levels in the general
population by evaluating the pooled control group. For this
purpose, we used linear regression to estimate mean dif-
ferences and their 95% CIs in levels of hemostatic factors
and CRP for the 10th–25th, 25th–75th, 75th–90th, and
[90th percentile categories of lipid levels in comparison
with the reference category (\10th percentile). Because
CRP levels showed a distribution skewed to the right, a
log-transformation was applied for this variable. In our
regression models, CRP (log-transformed) or each of the
hemostatic factors studied was entered as the dependent
variable, and the aforementioned lipid categories were the
independent variables. The resulting b coefficient for a
lipid category indicated the mean difference in levels of
hemostatic factors or CRP between that particular category
and the reference. Mean differences and their 95% CIs
were adjusted for age, sex, estrogen use at blood sampling,
BMI, statin use, and self-reported diabetes. We further used
linear regression to estimate the increase or decrease in
levels of hemostatic factors or CRP (log-transformed) for
every 1 unit increase in lipid levels after adjustment for the
same potential confounders. Controls (n = 27) who used
vitamin K antagonists at the time of blood draw were
excluded from the analyses of the vitamin K-dependent
factors.
Second, we repeated the earlier logistic regression
analyses, at this time including factors associated with lipid
levels. Hemostatic factors and CRP (log-transformed) were
introduced in the logistic regression model as continuous
variables. Patients (n = 271) and controls (n = 27) using
vitamin K antagonists at the time of blood draw were
excluded if vitamin K-dependent factors were added to the
model.
All statistical analyses were performed with SPSS for
Windows, release 20.0 (SPSS Inc, Chicago, IL).
Results
Clinical characteristics
Assessment of lipids was successful for over 99% of the
eligible participants, with a total of 2234 patients, 1455
partner and 1418 RDD controls (Fig. 2). Of the 1455
partners, 1185 were matched with patients. Table 1 shows
the baseline characteristics of the participants. There were
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no substantial age and sex differences between patients and
controls. BMI was higher in patients than in RDD controls
and it was virtually the same as in partners. Patients used
hormones more often at the index date than controls, and
controls were more likely to use hormones at blood sam-
pling, as most patients discontinued hormone use after
venous thrombosis. The percentage of self-reported dia-
betes was virtually the same among participants, and
controls used statins more often than patients. The median
time between the thrombotic event and blood collection
was 10.0 months (interquartile range 8.3–12.4 months).
Supplementary Table 1 (Online Resource) shows no sub-
stantial differences in the baseline characteristics of all
participants compared with those who provided blood
samples, indicating that the tested individuals were repre-
sentative of the whole MEGA group.
Demographic and clinical characteristics related
to lipid levels in controls
Variation in lipid levels according to demographic and
clinical characteristics in controls is detailed in Supple-
mentary Table 2 (Online Resource). Lipid levels increased
with age, and men (as compared with women) had higher
levels of LDL-C, triglycerides, and apo B and lower levels
of HDL-C and apo A1. Levels of HDL-C and apo A1 were
lower, whereas levels of the other lipids were higher in
overweight/obese controls than in those with normal
weight. TC, LDL-C, and apo B were, as expected, reduced
among statin users. Estrogen users had higher levels of
triglycerides, apo B, and apo A1 as compared with nonu-
sers. Except for triglycerides, self-reported diabetes was
associated with a reduction in lipid levels.
Lipid levels and risk of venous thrombosis
Table 2 lists the risk of venous thrombosis for percentile
categories of lipid levels. When partners and RDD controls
were pooled as the control group, TC, LDL-C, and
triglycerides levels were not associated with venous
thrombosis in the age- and sex-adjusted model and after
full adjustment. In contrast, decreasing apo B levels were
associated with an increasing venous thrombosis risk in the
pooled control analyses. In the age- and sex-adjusted
model, the lowest percentile category of apo B as com-
pared with the reference category resulted in a 1.35-fold
(95% CI 1.12–1.62) increased risk of venous thrombosis
(Table 2), and the association was strengthened with fur-
ther adjustment for BMI (OR 1.56, 95% CI 1.28–1.89).
Addition of the other potential confounders to the model
did not substantially change risk estimates, which increased
dose-dependently with the reduction of apo B levels across
percentile categories (Table 2).
In analyses using both control groups, decreasing HDL-
C and apo A1 levels were associated with an increasing
risk of venous thrombosis in a dose-dependent manner
(Table 2). Compared with the reference categories, the
lowest percentile categories of HDL-C and apo A1 yielded
odds ratio for venous thrombosis of 1.35 (95% CI
1.11–1.62) and 1.50 (95% CI 1.25–1.79), respectively.
With adjustment for BMI, the risk conferred by apo A1 was
attenuated (OR 1.33, 95% CI 1.10–1.60), whereas the risk
conferred by HDL-C virtually disappeared (OR 1.10, 95%
CI 0.91–1.35). After full adjustment, both risk estimates
did not substantially change, and the dose–response rela-
tion remained between apo A1 levels and venous throm-
bosis risk, as depicted in Table 2.
Table 1 Baseline characteristics
Patients
n = 2234
Partners
n = 1455
RDD
n = 1418
Partners ? RDD
n = 2873
Age, years 49 (26–67) 51 (29–66) 48 (24–67) 50 (27–67)
Women, n (%) 1217 (55) 746 (51) 763 (54) 1509 (53)
BMI (kg/m2) 26 (20–35) 26 (20–33) 25 (20–32) 25 (20–33)
Estrogen use at index date, n (% in women) 726 (61) 179 (25) 227 (30) 406 (28)
Estrogen use at blood sampling, n (% in women) 205 (18) 159 (23) 222 (30) 381 (26)
Statin use, n (%) 72 (3) 75 (5) 108 (8) 183 (6)
Self-reported diabetes, n (%) 72 (3) 46 (3) 41 (3) 87 (3)
Venous thrombosis
DVT, n (%) 1307 (59) NA NA NA
PE ± DVT, n (%) 927 (41) NA NA NA
Continuous variables are shown as median (5th percentile–95th percentile) and categorical variables as number (%)
Data were missing for some participants in some subgroups
RDD random-digit dialing, BMI body mass index, DVT deep vein thrombosis, PE pulmonary embolism, NA not applicable
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When the analysis was restricted to partners as the
control group, there was again no consistent association
between venous thrombosis and levels of TC, LDL-C,
triglycerides and HDL-C across percentile categories
(Table 2). Results for apo B and apo A1 were similar to
those obtained with the pooled control group, i.e., risk
estimates for venous thrombosis increased with decreasing
levels of apo B or apo A1.
Table 2 Risk of venous thrombosis by percentiles of lipid levels
Patients
(n = 2234)
Controls
(n = 2873)
Pooled control analyses Partner control analyses
OR (95% CI)a OR (95% CI)b OR (95%CI)a OR (95% CI)b
TC (mmol L-1)
\10th (\4.28) 217 (10) 286 (10) 0.94 (0.78–1.15) 1.04 (0.84–1.29) 1.09 (0.80–1.49) 1.21 (0.87–1.69)
10th–25th (4.28–4.84) 346 (15) 428 (15) 1.02 (0.87–1.21) 1.06 (0.89–1.26) 0.87 (0.69–1.11) 0.98 (0.75–1.27)
25th–75th (4.84–6.30) 1107 (50) 1431 (50) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
75th–90th (6.30–7.04) 332 (15) 441 (15) 0.98 (0.83–1.16) 0.96 (0.81–1.14) 0.74 (0.59–0.94) 0.78 (0.61–1.01)
[90th ([7.04) 232 (10) 287 (10) 1.07 (0.88–1.29) 1.00 (0.82–1.22) 0.80 (0.61–1.06) 0.82 (0.60–1.11)
LDL-C (mmol L-1)
\10th (\2.38) 213 (10) 282 (10) 0.92 (0.76–1.12) 1.09 (0.88–1.35) 1.16 (0.85–1.59) 1.42 (1.01–1.99)
10th–25th (2.38–2.87) 304 (14) 425 (15) 0.88 (0.75–1.04) 0.97 (0.81–1.15) 0.98 (0.75–1.26) 1.05 (0.79–1.39)
25th–75th (2.87–4.17) 1118 (51) 1414 (50) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
75th–90th (4.17–4.85) 342 (15) 425 (15) 1.03 (0.87–1.21) 1.02 (0.86–1.21) 0.92 (0.73–1.15) 0.88 (0.68–1.13)
[90th ([4.85) 228 (10) 282 (10) 1.05 (0.86–1.27) 0.98 (0.80–1.20) 0.93 (0.71–1.22) 0.96 (0.71–1.29)
Triglycerides (mmol L-1)
\10th (\0.79) 224 (10) 273 (10) 1.02 (0.84–1.25) 1.14 (0.92–1.40) 1.26 (0.92–1.72) 1.39 (0.99–1.95)
10th–25th (0.79–1.00) 309 (14) 441 (15) 0.89 (0.75–1.05) 0.95 (0.80–1.14) 0.94 (0.73–1.21) 1.01 (0.77–1.32)
25th–75th (1.00–1.88) 1104 (49) 1440 (50) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
75th–90th (1.88–2.58) 355 (16) 432 (15) 1.09 (0.93–1.29) 1.05 (0.88–1.24) 1.01 (0.80–1.27) 0.98 (0.76–1.26)
[90th ([2.58) 242 (11) 287 (10) 1.13 (0.93–1.36) 0.96 (0.79–1.18) 0.95 (0.72–1.24) 0.89 (0.66–1.20)
Apo B (g L-1)
\10th (\0.68) 292 (13) 285 (10) 1.35 (1.12–1.62) 1.54 (1.26–1.88) 1.30 (0.99–1.72) 1.49 (1.10–2.00)
10th–25th (0.68–0.80) 356 (16) 431 (15) 1.10 (0.93–1.29) 1.20 (1.01–1.42) 1.01 (0.79–1.28) 1.19 (0.92–1.54)
25th–75th (0.80–1.15) 1071 (48) 1435 (50) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
75th–90th (1.15–1.33) 313 (14) 425 (15) 1.00 (0.85–1.18) 0.91 (0.76–1.08) 0.95 (0.74–1.21) 1.06 (0.81–1.38)
[90th ([1.33) 202 (9) 297 (10) 0.92 (0.75–1.12) 0.84 (0.68–1.03) 0.98 (0.73–1.33) 1.01 (0.73–1.40)
HDL-C (mmol L-1)
\10th (\0.90) 272 (12) 289 (10) 1.35 (1.11–1.62) 1.12 (0.91–1.37) 1.04 (0.79–1.38) 0.90 (0.66–1.23)
10th–25th (0.90–1.07) 387 (17) 434 (15) 1.26 (1.07–1.48) 1.17 (0.99–1.39) 1.08 (0.85–1.36) 1.04 (0.81–1.34)
25th–75th (1.07–1.56) 1068 (48) 1449 (50) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
75th–90th (1.56–1.86) 330 (15) 421 (15) 1.03 (0.87–1.22) 1.12 (0.94–1.33) 1.12 (0.87–1.44) 1.14 (0.86–1.49)
[90th ([1.86) 177 (8) 280 (10) 0.82 (0.67–1.01) 0.97 (0.78-1.21) 0.79 (0.58-1.09) 0.80 (0.57-1.13)
Apo A1 (g L-1)
\10th (\1.09) 322 (14) 295 (10) 1.50 (1.25–1.79) 1.36 (1.12–1.64) 1.26 (0.97–1.65) 1.19 (0.89–1.60)
10th–25th (1.09–1.22) 347 (16) 429 (15) 1.09 (0.93–1.29) 1.02 (0.86–1.21) 0.98 (0.77–1.24) 0.91 (0.70–1.18)
25th–75th (1.22–1.59) 1107 (50) 1444 (50) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
75th–90th (1.59–1.81) 296 (13) 432 (15) 0.86 (0.73–1.02) 0.96 (0.80–1.15) 0.84 (0.66–1.08) 0.91 (0.69–1.19)
[90th ([1.81) 162 (7) 273 (10) 0.73 (0.59–0.90) 0.88 (0.70–1.10) 0.66 (0.47–0.93) 0.67 (0.47–0.97)
Data were missing for some participants in some subgroups
OR odds ratio, CI confidence interval, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, Apo B apolipoprotein B, HDL-C high-
density lipoprotein cholesterol, Apo A1 apolipoprotein A1
a Adjusted for age, sex and partnership (where applicable)
b Adjusted for age, sex, body mass index, estrogen use at blood sampling, statin use, self-reported diabetes, and partnership (where applicable)
ORb (full adjustment) for apo B and apo A1 is in bold
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As risks of venous thrombosis were apparently not
related with TC, LDL-C, triglycerides and HDL-C, these
lipids were not further considered in the subsequent
analyses.
Mediation analyses
In comparison with the reference category, an increment in
apo B levels across percentile categories was associated
with a consistent increase in levels of natural anticoagu-
lants (protein C, protein S, antithrombin, and TFPI), pro-
coagulant factors (fibrinogen, and factors II, VII, IX, X,
and XI), clot lysis time, and CRP (Table 3). With the
exception of fibrinogen, changes in hemostatic factor levels
were in the same direction for apo A1, i.e., as apo A1
increased, levels of protein C, and factors II, VII, IX, X,
and XI increased as well (Table 4). Among the procoagu-
lant factors, only factor VIII and von Willebrand factor
were not associated with apo B and apo A1. The behavior
of the aforementioned hemostatic factor and CRP levels
was the same when apo B and apo A1 were introduced
continuously in the model.
When CRP and the hemostatic factors associated with
apo B or apo A1 were added to the logistic regression
model (Table 5), risk estimates changed marginally for
either apolipoprotein as compared with the analyses
adjusted for all potential confounders, regardless the type
of control group used. When the potential mediators were
entered one by one in the model, results were similar to
those described in Table 5 for both apolipoproteins (data
not shown).
Discussion
In this large population-based case–control study, levels of
the major lipids (i.e., TC, LDL-C, triglycerides, or HDL-C)
were not associated with an increased risk of venous
thrombosis. In contrast, apo B and apo A1 appeared
inversely associated with venous thrombosis, as decreasing
levels of both apolipoproteins were associated with an
increased risk of venous thrombosis, also after adjustment
for potential confounders. Although apo B and to a lesser
extent apo A1 were associated with several hemostatic
factors and CRP, none of these factors explained the
association between these apolipoproteins and venous
thrombosis risk.
A previous meta-analysis demonstrated that mean levels
of triglycerides were higher and those of HDL-C lower in
venous thrombosis patients than in controls [6]. However,
the majority of the reports on lipids and venous thrombosis
in this meta-analysis were small case–control studies, and
controlling for several confounders had not been possible
[6]. Our results follow the majority of the longitudinal
studies published after the aforementioned meta-analysis
[6], that collectively showed little to no evidence of an
Table 3 Effect of percentiles of apolipoprotein B on the levels of hemostatic factors and c-reactive protein in control subjects
Mean levels Apo B continuous 
reference scale 
<10th 10th-25th 25th-75th 75th-90th >90th Apo B per
Percentile Percentile Percentile Percentile Percentile 1 g L-1 
(Apo B, <0.68g L-1) (Apo B, 0.68-0.80g L-1) (Apo B, 0.80-1.15g L-1) (Apo B, 1.15-1.33g L-1) (Apo B, >1.33g L-1) increase
(n=285) (n=431) (n=1435) (n=425) (n=297) (n=2873)
Hemostatic factors
Anticoagulant factors
Protein C (IU/dL)b 105 4 (1 to 7) 12 (9 to 14) 19 (16 to 23) 25 (21 to 30) 27 (24 to 31)
Protein S antigen (IU/dL)b 91 2 (-1 to 4) 8 (6 to 11) 13 (10 to 16) 16 (13 to 20) 21 (18 to 24)
Antithrombin (IU/dL) 103 3 (1 to 4) 5 (3 to 6) 7 (5 to 9) 7 (5 to 9) 8 (6 to 9)
TFPI activity (U/dL) 144 9 (4 to 15) 28 (22 to 34) 42 (34 to 49) 42 (34 to 50) 59 (53 to 66)
Procoagulant factors
Fibrinogen (g/L) 3.1 0 (-0.1 to 0.1) 0.1 (0 to 0.2) 0.2 (0.1 to 0.3) 0.2 (0.1 to 0.4) 0.4 (0.3 to 0.5)
Factor II (IU/dL)b 103 3 (1 to 5) 9 (7 to 11) 15 (11 to 18) 18 (15 to 21) 22 (20 to 24)
Factor VII (IU/dL)b 98 4 (0 to 7) 11 (8 to 14) 16 (12 to 19) 23 (18 to 27) 24 (21 to 28)
Factor VIII (IU/dL) 110 -5 (-10 to 1) -3 (-8 to 2) -4 (-11 to 3) 2 (-6 to 10) 3 (-3 to 8)
VWF (IU/dL) 108 -8 (-15 to 0) -6 (-12 to 0) -7 (-17 to 3) 1 (-10 to 12) 4 (-4 to 10)
Factor IX antigen (IU/dL)b 95 2 (0 to 4) 7 (5 to 10) 10 (7 to 13) 15 (12 to 19) 17 (15 to 20)
Factor X (IU/dL)b 108 3 (1 to 6) 10 (8 to 12) 15 (12 to 18) 21 (17 to 24) 23 (21 to 26)
Factor XI (IU/dL) 93 2 (-1 to 5) 7 (5 to 10) 12 (9 to 16) 11 (7 to 15) 15 (12 to 17)
Fibrinolytic factor
Clot lysis time (min)b 61 1 (-1 to 3) 6 (4 to 9) 10 (7 to 14) 14 (10 to 17) 17 (14 to 19)
Inflammatory marker
CRP (mg/L)c 0.2 -0.1 (-0.2 to 0.1) 0.1 (0 to 0.2) 0.2 (0 to 0.3) 0.3 (0.1 to 0.5) 0.4 (0.3 to 0.6)
Adjusteda mean difference (95% CI)
compared with the reference category 
Data were missing for some participants in some subgroups
Apo B apolipoprotein B, CI confidence interval, TFPI tissue factor pathway inhibitor, VWF von Willebrand factor, CRP C-reactive protein
a Adjusted for age, sex, body mass index, estrogen use at blood sampling, statin use, and self-reported diabetes
b Vitamin K antagonists users at the time of blood sampling were excluded from the analyses
c Log-transformed
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association between the major lipid levels and risk of
venous thrombosis [7, 10–12].
In contrast to the major lipids, fewer reports have
addressed the relationship between venous thrombosis and
levels of apo B and apo A1. In two cohort studies [8, 12]
neither apolipoprotein was associated with risk of venous
thrombosis. In the other reports, an association between
these apolipoproteins and venous thrombosis was restricted
to certain subgroups. For instance, in a small case–control
study composed of men only, low apo A1 levels were
associated with an increased risk of venous thrombosis
[29]. On the other hand, high apo A1 levels in the Women’s
Health Study were associated with an increased thrombosis
risk in hormone users [9]. In a hospital-based case–control
study, high apo B levels appeared to increase the risk of
venous thrombosis mainly in men [13]. Differences related
to the study design, the source and selection criteria of the
study population, the sample size, and the adjustment for
potential confounders might have contributed to the con-
tradictory results among these studies [8, 9, 12, 13, 29].
After excluding a major role for the most important
confounders in the association between venous thrombosis
and levels of apo B and apo A1, we investigated whether
this association might be explained by potential mediators.
Although apo B and to a lesser extent apo A1 levels were
associated with levels of several hemostatic factors and
CRP, their inclusion in the logistic regression model only
marginally affected risk estimates conferred by both
apolipoproteins, thereby excluding a mediating role for
these factors. Nevertheless, the strong association between
levels of apolipoproteins and hemostatic factors/CRP
deserves some further attention. We can hypothesize that
this may reflect a common mechanism, that influences the
synthesis of these proteins in hepatocytes [30–32]. In line
with this hypothesis was the finding that factor VIII and
von Willebrand factor, both largely expressed by
endothelial cells [31, 33], were not associated with apo B
or apo A1 levels. TFPI fits this hypothesis with respect to
apo A1 (no relation found), as it is also primarily synthe-
sized by endothelial cells [34]. The association between
total TFPI activity and apo B levels that was nevertheless
found is consistent with the fact that the majority of the
TFPI in plasma is bound to apo B-containing lipoproteins,
mainly LDL [34].
Here we observed a protective role for apo B against
venous thrombosis. Conversely, there is strong evidence
that elevated apo B and LDL-C are associated with
increased risk for arterial disease [35, 36]. Still, one should
consider that even though arterial and venous thrombosis
share some risk factors [1], their pathophysiology is dif-
ferent. An arterial thrombus is typically formed after rup-
ture of an atherosclerotic plaque, whereas venous thrombi
assemble on the surface of a largely intact vessel wall [37].
Based on this, it would be reasonable to consider that apo B
may play different roles in the mechanisms that are at the
basis of venous versus arterial thrombosis. Indeed, our
Table 4 Effect of percentiles of apolipoprotein A1 on the levels of hemostatic factors and c-reactive protein in control subjects
Mean levels ApoA1 continuous
reference  scale 
<10th 10th-25th 25th-75th 75th-90th >90th Apo A1 per
Percentile Percentile Percentile Percentile Percentile 1 g L-1 
(Apo A1, <1.09g L-1) (Apo A1, 1.09-1.22g L-1) (Apo A1, 1.22-1.59g L-1) (Apo A1, 1.59-1.81g L-1) (Apo A1, >1.81g L-1) increase
(n=295) (n=429) (n=1444) (n=432) (n=273) (n=2873)
Hemostatic factors
Anticoagulant factors
Protein C (IU/dL)b 111 4 (1 to 7) 6 (3 to 8) 12 (8 to 16) 15 (10 to 20) 15 (12 to 18)
Protein S antigen (IU/dL)b 101 2 (-1 to 5) 1 (-2 to 3) 1 (-2 to 5) 0 (-4 to 4) -2 (-5 to 1)
Antithrombin (IU/dL) 105 0 (-2 to 2) 0 (-2 to 1) 0 (-2 to 2) 1 (-2 to 4) 0 (-1 to 2)
TFPI activity (U/dL) 177 -2 (-9 to 5) -4 (-10 to 2) 0 (-9 to 9) -11 (-22 to 0) -3 (-10 to 4)
Procoagulant factors
Fibrinogen (g/L) 3.5 -0.2 (-0.3 to -0.1) -0.3 (-0.4 to -0.2) -0.4 (-0.5 to -0.2) -0.4 (-0.6 to -0.2) -0.3 (-0.4 to -0.2)
Factor II (IU/dL)b 109 2 (-1 to 5) 0 (-1 to 2) 2 (-1 to 5) 7 (3 to 11) 6 (4 to 8)
Factor VII (IU/dL)b 101 6 (2 to 9) 7 (4 to 10) 14 (9 to 18) 21 (15 to 26) 16 (13 to 20)
Factor VIII (IU/dL) 108 -1 (-7 to 4) -1 (-6 to 4) 6 (-2 to 15) 3 (-6 to 13) 3 (-2 to 9)
VWF (IU/dL) 107 2 (-6 to 10) -1 (-6 to 5) 3 (-5 to 11) 8 (-2 to 18) 1 (-6 to 7)
Factor IX antigen (IU/dL)b 103 1 (-2 to 3) 0 (-2 to 2) 2 (-2 to 5) 7 (3 to 12) 4 (2 to 6)
Factor X (IU/dL)b 113 3 (0 to 6) 5 (2 to 7) 8 (5 to 11) 18 (14 to 22) 14 (11 to 17)
Factor XI (IU/dL) 95 2 (-1 to 5) 3 (0 to 5) 4 (0 to 8) 6 (2 to 10) 5 (2 to 8)
Fibrinolytic factor 
Clot lysis time (min)b 72 0 (-3 to 3) -1 (-3 to 2) -2 (-6 to 2) -2 (-6 to 2) -1 (-4 to 1)
Inflammatory marker
CRP (mg/L)c 0.6 -0.2 (-0.3 to 0) -0.4 (-0.5 to -0.2) -0.3 (-0.5 to -0.1) -0.2 (-0.4 to 0.1) -0.2 (-0.3 to -0.1)
Adjusteda mean difference (95% CI)
compared with the reference category
Data were missing for some participants in some subgroups
Apo A1 apolipoprotein A1, CI confidence interval, TFPI tissue factor pathway inhibitor, VWF von Willebrand factor, CRP C-reactive protein
a Adjusted for age, sex, body mass index, estrogen use at blood sampling, statin use, and self-reported diabetes
b Vitamin K antagonists users at the time of blood sampling were excluded from the analyses
c Log-transformed
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results on the inverse association of apo B levels with risk
of venous thrombosis are consistent with experimental
studies demonstrating that apo B is capable of inhibiting
coagulation [38, 39]. In vitro, purified human apo B was
shown to inhibit TF-initiated coagulation either alone or
reconstituted into LDL-like particles in a thus far undefined
TFPI-independent manner [39]. Alternatively, apo B could
indirectly exert an anticoagulant function via LDL-bound
TFPI. The latter was shown to inhibit the coagulation
protease factor Xa activity more potently as compared with
the TF-FVIIa inhibition [40]. In the present study, we
assessed total plasma TFPI activity via inhibition of the
TF-FVIIa complex, which might explain why TFPI did not
mediate, at least in part, the association between apo B and
venous thrombosis risk.
It might be argued that our findings on apo B and venous
thrombosis are not consistent with the putative protection
conferred by statins against venous thrombosis [3–5], since
these drugs decrease apo B levels [41, 42]. It is noteworthy
that statins may have antithrombotic effects that are unre-
lated to their lipid-lowering activity, such as downregula-
tion of TF [43]. It is currently unknown, however, to what
extent the antithrombotic potential of statins would influ-
ence the thrombosis risk or the anticoagulant properties of
apo B demonstrated in vitro [38, 39].
Unlike apo B, risk estimates for venous thrombosis
associated with apo A1 pointed in the same direction to that
reported in observational studies on arterial disease [36].
Importantly, our results are consistent with experimental
data on the role of this apolipoprotein in protecting mice
against venous thrombosis [44]. It has been demonstrated
that flow restriction-induced venous thrombosis was more
common in apo A1-/- mice as compared with wild-type
mice, and intravenous infusion of human apo A1 prevented
venous thrombosis in wild-type mice but not in mice
lacking scavenger receptor B type I or endothelial nitric
oxide synthase [44]. The interaction between apo A1
within HDL-C and scavenger receptor B type I promotes
not only the reverse cholesterol transport but also has been
shown to stimulate the activation of endothelial nitric oxide
synthase [45], which results in the production of nitric
oxide. An impairment in nitric oxide bioavailability rep-
resents a central feature of endothelial cell activation and
dysfunction [46]. As endothelial activation could con-
tribute to venous thrombus formation [37], according to the
the murine model study [44] one of the possible mecha-
nisms by which apo A1 may protect against venous
thrombosis is the upregulation of nitric oxide production
and as a result the maintenance of endothelial integrity.
Additionally, apo A1 has been suggested to have antico-
agulant properties in vitro, as apo A1 was observed to play
a critical role in the ability of HDL to enhance the anti-
coagulant potential of the protein C pathway [21, 47].
The strengths of this study include the large patient
sample and the detailed assessment of the relationship
between lipids and venous thrombosis, considering not
only confounding by several common risk factors, but also
mediation via hemostatic factors. Estimation of venous
thrombosis risk using only partners as controls enabled us
to adjust for further confounding by socio-economic factors
[28]. Importantly, variation in lipid levels according to
demographic and clinical characteristics in controls (age,
sex, BMI, and estrogen- and statin-use) agreed with pre-
vious findings [2, 14, 15, 18, 19]. Furthermore, our results
contributed to clarify the protective role of apo A1 against
venous thrombosis, confirming prior findings from a case–
control study [29] and a murine model of venous throm-
bosis [44]. Our study is the first, to our knowledge, to show
that apo B levels are also inversely associated with risk of
venous thrombosis, a finding supported by the anticoagu-
lant properties of this apolipoprotein observed in vitro
[38, 39].
Since this is an etiologic study, alternative explanations
for our results should be addressed and considered as
potential limitations. First, we cannot rule out that chance
has played a role in our results. Still, chance seems an
unlikely explanation owing to the dose–response associa-
tion between the risk of venous thrombosis and levels of
apo B and apo A1 in most of our models. Second, one
could argue that sampling of the blood after the event of
venous thrombosis might have resulted in reverse causa-
tion, i.e., the venous thrombotic event has led to changes in
lipid levels. Indeed, after venous thrombosis, patients may
have modified certain lifestyle factors, which could have
affected their lipid profile. Randomized clinical trials
published during the nineties showed that changes in diet
affected lipid levels in individuals with dyslipidemia
[48, 49]. However, the reduction in the levels of TC, LDL-
C and apo B produced by a low-fat diet taken from 9 weeks
to 1 year in these trials was small or virtually absent
without concomitant statin use or aerobic-exercise program
[48, 49]. It is quite unlikely that venous thrombosis patients
would systematically adhere to a low-fat diet in addition to
statin use and/or exercise after the thrombotic event,
especially considering that such recommendation is not
routinely given, in contrast to arterial disease. Another
mechanism for reverse causation would be the effect of
acute phase reactions brought about by the thrombotic
event on lipid levels [50, 51]. During acute phase reactions
in humans, triglyceride levels typically increase and HDL-
C and apo A1 levels decrease, whereas TC, LDl-C and apo
B levels can either decrease or do not change [50, 51].
Nevertheless, this is an unlikely mechanism for reverse
causation, since blood was collected with a median of
10 months after the thrombotic event, by which time the
effects of the acute-phase reaction will have worn off
678 V. M. Morelli et al.
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[52, 53]. Third, low cholesterol levels have been reported
in some chronic illnesses, such as malignancy, rheumatic
disorders, hyperthyroidism and tuberculosis [54]. Hence,
these illnesses could have been confounding factors but
subjects with malignancy were excluded from the current
analyses. Furthermore, changes in lipid levels in our study
population owing to reverse causation or chronic illnesses
would be expected to affect not only the direction of the
point estimates related to the apolipoproteins but also to the
other lipids, such as TC, which also makes it unlikely that
our findings can be due to either of these explanations.
Fourth, even though it is reasonable to assume that patients
and their partners likely have a similar lifestyle, lipid levels
could be influenced by factors that couples may not share,
such as physical activity or diet. Thereby, we cannot rule
out the possibility of residual lifestyle-related confounders.
However, to reduce this possibility, in the conditional
regression analyses we also included in our models BMI,
statin use, and diabetes as potential sources of confounding
related to lifestyle. Finally, LDL-C was not assessed
directly but estimated by the Friedewald formula [25].
From an analytical perspective, estimation of LDL-C was
the sum of the inaccuracies and imprecision of three
measurements [TC, HDL-C and triglyceride], whereas apo
B was measured by a direct and standardized method
[23, 55].
In conclusion, in this large, unselected population we
showed no association between levels of TC, LDL-C,
HDL-C and triglycerides and risk of venous thrombosis.
Decreasing levels of apolipoproteins B and A1 were
associated with increased risk of venous thrombosis,
which we could not explain through several proposed
mechanisms, such as confounding or other non-causal
explanations, or through mediation via inflammation or
changes in the hemostatic factors. Our results may form
the basis for further studies to confirm these findings, as
well as to assess the physiological relevance of the
anticoagulant properties of apo B and apo A1, and to
determine the mechanism, whether or not causal, under-
lying the link between these apolipoproteins and venous
thrombosis.
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